
    
      Chidamideï¼Œa novel histone deacetylase inhibitor has been approved for the treatment of
      relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to
      observe the efficacy and safety of Chidamide combined with DICE in patients with relapsed or
      refractory B-cell Non-Hodgkin's Lymphoma (NHL).
    
  